Tibet Rhodiola Pharmaceutical Holding Co. (600211.SS)
CNY 37.17
(0.38%)
CNY 37.17
(0.38%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 3.09 Billion | 2.55 Billion | 2.13 Billion | 1.37 Billion | 1.25 Billion | 1.02 Billion |
| Cost of Revenue | 155.08 Million | 146.69 Million | 223.21 Million | 194.96 Million | 206.64 Million | 206.37 Million |
| Gross Profit | 2.94 Billion | 2.4 Billion | 1.91 Billion | 1.17 Billion | 1.04 Billion | 821.5 Million |
| Operating Expenses | 2.07 Billion | 1.65 Billion | 1.33 Billion | 719.27 Million | 704.45 Million | 500.37 Million |
| Selling, General and Administrative Expenses | 1.79 Billion | 1.45 Billion | 1.19 Billion | 719.2 Million | 654.81 Million | 512.21 Million |
| Research and Development Expenses | 17.35 Million | 88.13 Million | 60.85 Million | 7.45 Million | 11.07 Million | 8.2 Million |
| Other Expenses | 177.76 Million | 110.87 Million | 78.76 Million | -7.39 Million | 38.57 Million | -20.05 Million |
| Cost and Expenses | 2.23 Billion | 1.8 Billion | 1.56 Billion | 914.23 Million | 911.09 Million | 706.74 Million |
| Operating Income | 899.09 Million | 768.03 Million | 565.24 Million | 472.11 Million | 351.22 Million | 331.47 Million |
| Interest Expense | 11.59 Million | 14.35 Million | 4.32 Million | 1.04 Million | 1.05 Million | 274.28 Thousand |
| Income Tax Expense | 87.94 Million | 88.11 Million | 41.82 Million | 49.65 Million | 35.29 Million | 26.34 Million |
| Earnings before Tax | 898.19 Million | 463.39 Million | 254.85 Million | 470.31 Million | 352.66 Million | 244.43 Million |
| Net Income | 800.91 Million | 369.83 Million | 208.93 Million | 418.09 Million | 312.32 Million | 215.6 Million |
| Earnings Per Share Basic | 2.48 | 1.49 | 0.84 | 1.69 | 1.25 | 0.86 |
| Earnings Per Share Diluted | 2.48 | 1.49 | 0.84 | 1.69 | 1.25 | 0.86 |
| Weighted Average Shares Outstanding | 322.35 Million | 247.93 Million | 247.93 Million | 247.93 Million | 249.85 Million | 251.46 Million |
| Weighted Average Shares Outstanding (Diluted) | 322.35 Million | 247.93 Million | 247.93 Million | 247.93 Million | 249.85 Million | 251.54 Million |
| Gross Margin | 0.95 | 0.94 | 0.90 | 0.86 | 0.84 | 0.80 |
| EBIT Margin | 0.32 | 0.33 | 0.30 | 0.40 | 0.34 | 0.40 |
| Profit Margin | 0.26 | 0.14 | 0.10 | 0.30 | 0.25 | 0.21 |
| EBITDA | 976.16 Million | 551.18 Million | 351.31 Million | 558.09 Million | 433.14 Million | 321.24 Million |
| Earnings Before Tax Margin | 0.29 | 0.30 | 0.26 | 0.34 | 0.28 | 0.32 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 554.19 Million | 893.5 Million | 697.3 Million | 3.09 Billion | 756.38 Million | 547.77 Million |
| Cost of Revenue | 40.83 Million | 41.79 Million | 36.39 Million | 181.07 Million | 51.49 Million | 33.93 Million |
| Gross Profit | 513.35 Million | 851.71 Million | 660.91 Million | 2.91 Billion | 704.89 Million | 513.83 Million |
| Operating Expenses | 337.86 Million | 538.72 Million | 424.36 Million | 1.87 Billion | 657.56 Million | 232.37 Million |
| Selling, General and Administrative Expenses | 331.36 Million | 532.03 Million | 421.44 Million | - | 458.3 Million | 373.38 Million |
| Research and Development Expenses | 6.5 Million | 6.64 Million | 2.92 Million | - | 8.4 Million | 491.04 Thousand |
| Other Expenses | 60.00 | -48.05 Thousand | 173.53 Thousand | -2.77 Million | -190.84 Million | 143.46 Thousand |
| Cost and Expenses | 378.7 Million | 580.52 Million | 460.75 Million | 2.05 Billion | 709.06 Million | 266.31 Million |
| Operating Income | 175.48 Million | 312.98 Million | 236.55 Million | 1.03 Billion | 47.32 Million | 290.28 Million |
| Interest Expense | 3.95 Million | 2.84 Million | 2.41 Million | 11.59 Million | 2.58 Million | 4.16 Million |
| Income Tax Expense | 17.88 Million | 37.59 Million | 32.19 Million | 87.94 Million | -3.19 Million | 26.74 Million |
| Earnings before Tax | 187.66 Million | 349.25 Million | 348.19 Million | 902.46 Million | -54.43 Million | 290.43 Million |
| Net Income | 168.73 Million | 310.21 Million | 312.91 Million | 800.91 Million | -54.42 Million | 259.43 Million |
| Earnings Per Share Basic | 0.52 | 0.96 | 1.26 | - | -0.22 | 1.05 |
| Earnings Per Share Diluted | 0.52 | 0.96 | 1.26 | - | -0.22 | 1.05 |
| Weighted Average Shares Outstanding | 322.31 Million | 322.31 Million | 247.93 Million | 247.93 Million | 247.93 Million | 247.93 Million |
| Weighted Average Shares Outstanding (Diluted) | 322.31 Million | 322.31 Million | 247.93 Million | 247.93 Million | 247.93 Million | 247.93 Million |
| Gross Margin | 0.93 | 0.95 | 0.95 | 0.94 | 0.93 | 0.94 |
| EBIT Margin | 0.35 | 0.37 | 0.50 | - | 0.07 | 0.54 |
| Profit Margin | 0.30 | 0.35 | 0.45 | 0.26 | -0.07 | 0.47 |
| EBITDA | 191.62 Million | 331.44 Million | 351.8 Million | - | 55.96 Million | 294.74 Million |
| Earnings Before Tax Margin | 0.32 | 0.35 | 0.34 | 0.34 | 0.06 | 0.53 |
LABS
TBEV
MVP
CDBDF
UPPR
TANA